8:30 am Oxygen Biotherapeutics: recent scientific publications highlight potential benefits of Levosimendan in cardiac surgery and additional critical care conditions (OXBT) : Co highlighted three recent review articles examining the current clinical use of levosimendan and its potential to address a wide range of critical care conditions. Oxygen is currently preparing to initiate a Phase 3 trial in the United States during the third quarter to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome.
Summaries of the review articles are as follows:
Levosimendan: points to "a range of beneficial haemodynamic and cardio protective effects, and a favourable influence on clinical outcomes." The article also points to preliminary positive observations in additional conditions that require inotropic support -- such as right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy.
Preoperative Levosimendan: The authors highlight that "through this triple mechanism, levosimendan increases the contractile force of the cardiac muscle fibers, cause both peripheral arterial and venous vasodilation, and exerts a cardio protective effect against ischemia.
News 
Market Data 
Discover 
